| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | 645.49% | HC Wainwright & Co. | $8 → $5 | Maintains | Buy |
| 08/18/2023 | 1092.78% | HC Wainwright & Co. | → $8 | Upgrades | Neutral → Buy |
| 03/14/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 08/17/2021 | 645.49% | HC Wainwright & Co. | $7 → $5 | Maintains | Buy |
| 08/13/2020 | 25.24% | Credit Suisse | $0.69 → $0.84 | Maintains | Underperform |
| 07/20/2020 | 2.88% | Credit Suisse | $1 → $0.69 | Downgrades | Neutral → Underperform |
| 03/17/2020 | 943.69% | HC Wainwright & Co. | $9 → $7 | Maintains | Buy |
| 11/11/2019 | 198.2% | Credit Suisse | $7 → $2 | Downgrades | Outperform → Neutral |
| 08/05/2019 | 943.69% | Credit Suisse | → $7 | Assumes | → Outperform |
| 07/10/2019 | — | Credit Suisse | Assumes | → Outperform | |
| 04/24/2019 | — | B. Riley Securities | Initiates Coverage On | → Buy | |
| 02/15/2019 | 943.69% | Credit Suisse | → $7 | Initiates Coverage On | → Outperform |
| 10/23/2018 | 1241.88% | B. Riley Securities | → $9 | Initiates Coverage On | → Buy |
| 10/15/2018 | 1092.78% | Jefferies | → $8 | Upgrades | Hold → Buy |
| 10/10/2018 | 1390.98% | Ladenburg Thalmann | $7 → $10 | Reiterates | Buy → Buy |
What is the target price for AcelRx Pharmaceuticals (ACRX)?
The latest price target for AcelRx Pharmaceuticals (NASDAQ: ACRX) was reported by HC Wainwright & Co. on September 25, 2023. The analyst firm set a price target for $5.00 expecting ACRX to rise to within 12 months (a possible 645.49% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AcelRx Pharmaceuticals (ACRX)?
The latest analyst rating for AcelRx Pharmaceuticals (NASDAQ: ACRX) was provided by HC Wainwright & Co., and AcelRx Pharmaceuticals maintained their buy rating.
When is the next analyst rating going to be posted or updated for AcelRx Pharmaceuticals (ACRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AcelRx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AcelRx Pharmaceuticals was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
Is the Analyst Rating AcelRx Pharmaceuticals (ACRX) correct?
While ratings are subjective and will change, the latest AcelRx Pharmaceuticals (ACRX) rating was a maintained with a price target of $8.00 to $5.00. The current price AcelRx Pharmaceuticals (ACRX) is trading at is $0.67, which is out of the analyst's predicted range.